About Comet Therapeutics
Comet Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2017 by Enej Kuscer, and was acquired by VectivBio in August 2021. Enzyme substitution therapy for neurological diseases is developed. Comet Therapeutics has raised $28.5 million across 1 funding round from investors including Canaan, VectivBio and Mission BioCapital. The company was acqui-hired. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Comet Therapeutics was founded in 2017 and is based in Cambridge, United States. Therapies for neurological diseases are developed through enzyme substitution approaches. Orphan neurological disorders are addressed via Coenzyme-A substitution methods. The CoEnzyme metabolism (CoMET) platform has been established to restore dysregulated CoEnzyme A metabolism in affected patients. Operations center on advancing treatments within the biotechnology sector for rare conditions.
- Headquarters Cambridge, United States
- Founders Enej Kuscer
- Stage Acquired
- SectorsHealthcare
- Website comettherapeutics.com
- Social LinkedIn X
- Acquired by VectivBio (Aug 2021)
Funding Insights of Comet Therapeutics
Comet Therapeutics has successfully raised a total of $28.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $28.5 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.5M
- Total Rounds 1
- Last Round Series A — $28.5M
- First Round $28.5M
(Jun 2019)
- Investors Count 4
All 1 funding rounds of Comet Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $28.5M | Series A | – | Canaan, Sofinnova Partners |
5 investors in total: 5 institutional.
Investors in Comet Therapeutics
Comet Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Canaan, VectivBio and Mission BioCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
AI, deeptech, and healthcare tech companies are funded by Inkef. | inkef.com | Amsterdam, Netherlands | ||
Transformative therapeutics for rare diseases are developed. | 2019 | vectivbio.com | Basel, Switzerland |
Investor details for Comet Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Comet Therapeutics
1 people are tracked at Comet Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Enej Kuscer | Founder | Leadership |
Complete people profiles for Comet Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Comet Therapeutics
3 dated milestones of Comet Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Comet Therapeutics is founded.
- Funding First funding round of $28.5M.
- Exit Acquired by VectivBio.
Competitors of Comet Therapeutics
Comet Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. |
Detailed competitors of Comet Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Comet Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Comet Therapeutics
Complete news archive for Comet Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Comet Therapeutics
Comet Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Comet Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Comet Therapeutics is a funded company, having raised a total of $28.5M across 1 funding round to date. The company's 1st funding round was a Series A of $28.5M, raised on Jun 2019.
Comet Therapeutics was founded in 2017 and is based in Cambridge, United States. Therapies for neurological diseases are developed through enzyme substitution approaches. Orphan neurological disorders are addressed via Coenzyme-A substitution methods. The CoEnzyme metabolism (CoMET) platform has been established to restore dysregulated CoEnzyme A metabolism in affected patients. Operations center on advancing treatments within the biotechnology sector for rare conditions.
Comet Therapeutics's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
Comet Therapeutics has 5 investors. Key investors include Canaan, VectivBio, Mission BioCapital, Sofinnova Partners, and Inkef.
Yes. Comet Therapeutics was acquired by VectivBio in August 2021.